Severe Acute Respiratory Syndrome Coronavirus 2
45
0
2
23
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.1%
5 terminated out of 45 trials
82.1%
-4.4% vs benchmark
13%
6 trials in Phase 3/4
13%
3 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (45)
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
Pulmonary Fibrosis During Severe COVID-19 Pneumonia
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
Pro-thrombotic Status in Patients with SARS-Cov-2 Infection
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection
A Clinical Trial of COVAC-2 in Adults
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression
A Clinical Trial of COVAC-2 in Healthy Adults
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
Host-pathogen Interactions During SARS-CoV-2 Infection
Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection
ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19
Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
A Clinical Trial of COVAC-1, a COVID-19 Vaccine, in Generally Healthy Adults
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia